These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

392 related articles for article (PubMed ID: 22213684)

  • 61. Determination of therapeutics with growth-hormone secretagogue activity in human urine for doping control purposes.
    Thevis M; Wilkens F; Geyer H; Schänzer W
    Rapid Commun Mass Spectrom; 2006; 20(22):3393-402. PubMed ID: 17051614
    [TBL] [Abstract][Full Text] [Related]  

  • 62. In vitro metabolism of tiletamine, zolazepam and nonbenzodiazepine sedatives: Identification of target metabolites for equine doping control.
    Fenwick SJ; Scarth JP
    Drug Test Anal; 2011 Oct; 3(10):705-16. PubMed ID: 21916022
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Detection and characterization of prednisolone metabolites in human urine by LC-MS/MS.
    Matabosch X; Pozo OJ; Pérez-Mañá C; Papaseit E; Segura J; Ventura R
    J Mass Spectrom; 2015 Mar; 50(3):633-42. PubMed ID: 25800201
    [TBL] [Abstract][Full Text] [Related]  

  • 64. New drostanolone metabolites in human urine by liquid chromatography time-of-flight tandem mass spectrometry and their application for doping control.
    Liu Y; Lu J; Yang S; Zhang Q; Xu Y
    Steroids; 2016 Apr; 108():61-7. PubMed ID: 26826321
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Fragmentation studies of SIRT1-activating drugs and their detection in human plasma for doping control purposes.
    Höppner S; Schänzer W; Thevis M
    Rapid Commun Mass Spectrom; 2013 Jan; 27(1):35-50. PubMed ID: 23239315
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Implementation of the HIF activator IOX-2 in routine doping controls - Pilot study data.
    Görgens C; Guddat S; Bosse C; Knoop A; Geyer H; Thevis M
    Drug Test Anal; 2020 Nov; 12(11-12):1614-1619. PubMed ID: 32809277
    [TBL] [Abstract][Full Text] [Related]  

  • 67. A novel HPLC-MRM strategy to discover unknown and long-term metabolites of stanozolol for expanding analytical possibilities in doping-control.
    Wang Z; Zhou X; Liu X; Dong Y; Zhang J
    J Chromatogr B Analyt Technol Biomed Life Sci; 2017 Jan; 1040():250-259. PubMed ID: 27842983
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Doping control analysis of selected peptide hormones using LC-MS(/MS).
    Thevis M; Thomas A; Schänzer W
    Forensic Sci Int; 2011 Dec; 213(1-3):35-41. PubMed ID: 21752560
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Liquid chromatography-tandem mass spectrometry screening method for the simultaneous detection of stimulants and diuretics in urine.
    Hsu KF; Chien KY; Chang-Chien GP; Lin SF; Hsu PH; Hsu MC
    J Anal Toxicol; 2011 Nov; 35(9):665-74. PubMed ID: 22080905
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Urine analysis concerning xenon for doping control purposes.
    Thevis M; Piper T; Geyer H; Schaefer MS; Schneemann J; Kienbaum P; Schänzer W
    Rapid Commun Mass Spectrom; 2015 Jan; 29(1):61-6. PubMed ID: 25462364
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Doping control analysis for adrafinil and its major metabolites in human urine.
    Lu J; Wang X; Yang S; Liu X; Qin Y; Shen L; Wu Y; Xu Y; Wu M; Ouyang G
    Rapid Commun Mass Spectrom; 2009 Jun; 23(11):1592-600. PubMed ID: 19399790
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Use of LC-MS/MS for the open detection of steroid metabolites conjugated with glucuronic acid.
    Fabregat A; Pozo OJ; Marcos J; Segura J; Ventura R
    Anal Chem; 2013 May; 85(10):5005-14. PubMed ID: 23586472
    [TBL] [Abstract][Full Text] [Related]  

  • 73. A simplified procedure for the analysis of formoterol in human urine by liquid chromatography-electrospray tandem mass spectrometry: application to the characterization of the metabolic profile and stability of formoterol in urine.
    Mazzarino M; de la Torre X; Fiacco I; Pompei C; Calabrese F; Botrè F
    J Chromatogr B Analyt Technol Biomed Life Sci; 2013 Jul; 931():75-83. PubMed ID: 23777613
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Doping control analysis of methoxyphenamine using liquid chromatography-tandem mass spectrometry.
    Thevis M; Sigmund G; Koch A; Guddat S; Maurer HH; Schänzer W
    Eur J Mass Spectrom (Chichester); 2008; 14(3):145-52. PubMed ID: 18708694
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Liposomes as potential masking agents in sport doping. Part 1: analysis of phospholipids and sphingomyelins in drugs and biological fluids by aqueous normal-phase liquid chromatography-tandem mass spectrometry.
    Esposito S; Colicchia S; de la Torre X; Mazzarino M; Botrè F
    Drug Test Anal; 2017 Jan; 9(1):75-86. PubMed ID: 26857656
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Mass spectrometric characterization of a biotechnologically produced full-length mechano growth factor (MGF) relevant for doping controls.
    Thevis M; Thomas A; Geyer H; Schänzer W
    Growth Horm IGF Res; 2014 Dec; 24(6):276-80. PubMed ID: 25466910
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Generic sample preparation and dual polarity liquid chromatography-time-of-flight mass spectrometry for high-throughput screening in doping analysis.
    Kolmonen M; Leinonen A; Kuuranne T; Pelander A; Ojanperä I
    Drug Test Anal; 2009 Jun; 1(6):250-66. PubMed ID: 20355204
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Comparison of sulfo-conjugated and gluco-conjugated urinary metabolites for detection of methenolone misuse in doping control by LC-HRMS, GC-MS and GC-HRMS.
    Fragkaki AG; Angelis YS; Kiousi P; Georgakopoulos CG; Lyris E
    J Mass Spectrom; 2015 May; 50(5):740-8. PubMed ID: 26259657
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Identification of fentanyl, alfentanil, sufentanil, remifentanil and their major metabolites in human urine by liquid chromatography/tandem mass spectrometry for doping control purposes.
    Thevis M; Geyer H; Bahr D; Schänzer W
    Eur J Mass Spectrom (Chichester); 2005; 11(4):419-27. PubMed ID: 16204809
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Mass spectrometric determination of gonadotrophin-releasing hormone (GnRH) in human urine for doping control purposes by means of LC-ESI-MS/MS.
    Thomas A; Geyer H; Kamber M; Schänzer W; Thevis M
    J Mass Spectrom; 2008 Jul; 43(7):908-15. PubMed ID: 18563864
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.